Biological NI-1801

Phase 1Small molecule

LLight Chain Bioscience - Novimmune SA

Biological NI-1801 is one of 50 small molecule programs targeting Solid Cancers. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Solid CancersRecruiting

Colorectal CancerRecruiting

Solid CancersPhase 1

Recruiting

Colorectal CancerPhase 1

Recruiting

Competition

Competitive Landscape

268 competitors in Colorectal Cancer

#DrugCompanyPhaseTrials

Camptosar

Pfizer

Phase 3

34 2

Fudr

Pfizer

Phase 3

16 3

Tyvyt

Innovent Biologics (Suzhou) Co. Ltd.

Phase 3

8 4

Botensilimab

AAgenus Inc.

Phase 3

10 5

Zanzalintinib

Merck & Co.

Phase 3

1 6

5-Fu

TToray Industries, Inc

Phase 3

3 7

Cadonilimab

SShanghai Pharmaceuticals Holding Co., Ltd

Phase 3

2 8

BL-M07D1

SSichuan Baili Pharmaceutical Co., Ltd.

Phase 3

1 9

TQB2102

CChia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

Phase 3

1 10

Calcium Levofolinate

FFujian Cancer Hospital

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 1Recruiting

Solid Cancers

NCT05403554

Clinical

Trials by Indication[1]

Colorectal Cancer1 trial

A Study of NILK-2301 in Patients with Locally Advanced or Metastatic Low Tumor Volume (LTV) Colorectal Cancer

Recruiting·LLight Chain Bioscience - Novimmune SA·Phase 1·NCT06663839·25 enrolled

Solid Cancers1 trial

A Study of NI-1801 in Patients with Mesothelin Expressing Solid Cancers

Recruiting·LLight Chain Bioscience - Novimmune SA·Phase 1·NCT05403554·70 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Biological NI-1801. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Biological NI-1801 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Biological NI-1801. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Light Chain Bioscience - Novimmune SA company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: LLight Chain Bioscience - Novimmune SA

Biological NI-1801

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Trials by Indication[1]

Colorectal Cancer1 trial

Solid Cancers1 trial

References

Drug Info

Quick Facts

Related News